

**SUGGESTED FORMULA****Cantharidin 0.7% Topical Escharotic Suspension**

Version number: 1.0

Volume: 100mL

---

Cantharidin	0.7gm
Hydroxypropyl Cellulose 1500cps, NF	1gm
Acetone, NF (AC115)	50mL
Collodion (Flexible), USP (CO125)	Q.S. 100mL

---

**The final preparation is flammable.**

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator

**SUGGESTED COMPOUNDING PROCEDURES**

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Prepare a paste with Cantharidin with 25-mL acetone. Add balance of 25-mL acetone to mixture
4. Add Hydroxypropyl cellulose 1500 cps and acetone mixture to an amber calibrated bottle and allow mixture to dissolve
5. Bring to volume to 100mL with Flexible Collodion.
6. Package in glass and label, Affix warning labels.
7. Suggested Quality Assessments – follow pharmacy SOPs:
  - a. Weight to Volume calculation
  - b. Color
  - c. Pourability
  - d. Settling
  - e. Resuspendability

**\*For application in physician's office only. Not to be applied by the patient or the patient's caregiver**

Store in air tight amber glass containers at room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date should be assigned according to the current USP <795> Standards**

\*Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.  
9/19 JD